Currently, the cyclin‐dependent kinase (CDK) 4/6 inhibitor combined with an aromatase inhibitor is the first‐line therapy for patients with HR+, HER2− advanced BC.3, 4. The gene discussed is ERBB2; the disease is breast cancer.